Haemonetics reported a strong second quarter of fiscal 2027, beating consensus estimates on both revenue and earnings. Performance was anchored by double-digit organic growth in the Apheresis segment and significant expansion in adjusted gross margins, prompting management to raise full-year organic revenue expectations while slightly tempering operating margin expansion targets.
Key Highlights
- Revenue rose 9.3% to $357.8 million, surpassing analyst estimates of $345.2 million.
- Organic revenue growth reached 10.0%, driven primarily by a 13.6% organic increase in the Apheresis business unit.
- Management raised fiscal 2027 organic revenue guidance to a range of 6-9%, up from the previous 4-7% projection.
- Adjusted gross margin expanded 140 basis points to 61.9%, benefiting from tariff refunds and a shift toward higher-margin product offerings.
- Fiscal 2027 adjusted operating margin expansion guidance was lowered to 0-50 basis points from the previous 50-100 basis points range, reflecting higher personnel and freight costs.